James M. Frates - Aug 23, 2023 Form 4/A - Amendment Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role: Chief Financial Officer
Signature: /s/ Joshua B. Cohen, as Attorney in Fact
Stock symbol: AMLX
Transactions as of: Aug 23, 2023
Transactions value $: $124,975
Form type: 4/A - Amendment
Date filed: 9/5/2024, 07:55 PM
Date Of Original Report: Aug 24, 2023
Previous filing: Jun 16, 2023
Next filing: Nov 2, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMLX	Common Stock	Options Exercise	$125K	+18.2K	+32.63%	$6.88	73.8K	Aug 23, 2023	Direct	F1
holding	AMLX	Common Stock						19.5K	Aug 23, 2023	By Trust	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMLX	Stock Option (right to buy)	Options Exercise	$0	-18.2K	-4.76%	$0.00	364K	Aug 23, 2023	Common Stock	18.2K	$6.88	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On August 24, 2023, a Form 4 was filed on behalf of the Reporting Person which inadvertently overstated the number of securities reported in Column 5 of Table I by 32,500 shares due to an administrative error. This Form 4 amendment is being filed to correct the aggregate number of shares beneficially owned by the Reporting Person as of the original transaction date, as well as the corresponding amounts that were carried forward on Form 4 reports subsequently filed on behalf of the Reporting Person.
F2	Shares held by the James M. Frates Grantor Retained Annuity Trust 2021, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
F3	113,024 shares underlying this option vested on January 25, 2022, with the remaining shares vesting in monthly installments of 9,416 shares thereafter.